

Vol. 281, Issue 1, 460-463, 1997

## Inhibition by Boswellic Acids of Human Leukocyte Elastase

Hasan Safayhi, Beatrice Rall, Eckart-Roderich Sailer and Hermann P T. Ammon

Department of Pharmacology, Institute of Pharmaceutical Sciences, University of Tuebingen, Tuebingen, Germany

- ▶ [Abstract of this Article](#)
- ▶ [Reprint \(PDF\) Version of this Article](#)
- ▶ [eLetters: Submit a response to this article](#)
- ▶ Similar articles found in:
  - [JPET Online](#)
  - [PubMed](#)
- ▶ [PubMed Citation](#)
- ▶ This Article has been cited by:
  - [other online articles](#)
- ▶ Search Medline for articles by:
  - [Safayhi, H. || Ammon, H. P T.](#)
- ▶ Alert me when:
  - [new articles cite this article](#)
- ▶ [Download to Citation Manager](#)

### Abstract

Frankincense extracts and boswellic acids, biologically active pentacyclic triterpenes of frankincense, block leukotriene biosynthesis and exert potent anti-inflammatory effects. Screening for additional effects of boswellic acids on further proinflammatory pathways, we observed that acetyl-11-keto- $\beta$ -boswellic acid, an established direct, nonredox and noncompetitive 5-lipoxygenase inhibitor, decreased the activity of human leukocyte elastase (HLE) *in vitro* with an  $IC_{50}$  value of about 15  $\mu$ M.

Among the pentacyclic triterpenes tested in concentrations up to 20  $\mu$ M, we also observed substantial inhibition by  $\beta$ -boswellic acid, amyrin and ursolic acid, but not by 18 $\beta$ -glycyrrhetic acid. The data show that the dual inhibition of 5-lipoxygenase and HLE is unique to boswellic acids: other pentacyclic triterpenes with HLE inhibitory activities (*e.g.*, ursolic acid and amyrin) do not inhibit 5-lipoxygenase, and leukotriene biosynthesis inhibitors from different chemical classes (*e.g.*, NDGA, MK-886 and ZM-230,487) do not impair HLE activity. Because leukotriene formation and HLE release are increased simultaneously by neutrophil stimulation in a variety of inflammation- and hypersensitivity-based human diseases, the reported blockade of two proinflammatory enzymes by boswellic acids might be the rationale for the putative antiphlogistic activity of acetyl-11-keto- $\beta$ -boswellic acid and derivatives.

- ▲ [Top](#)
- [Abstract](#)
- ▼ [Introduction](#)
- ▼ [Materials & Methods](#)
- ▼ [Results](#)
- ▼ [Discussion](#)
- ▼ [References](#)

### Introduction

Frankincense is a gum resin secreted by trees of the genus *Boswellia* of Burseraceae. From the very beginning of human civilization, it has been used for therapeutic purposes (Martinetz *et al.*, 1988<sup>□</sup>). In Europe, it was a component of the pharmacopoeia until the beginning of this century, and then, with the onset of the era of synthetic drugs, it fell into oblivion. Frankincense is still used in the

- ▲ [Top](#)
- ▲ [Abstract](#)
- [Introduction](#)
- ▼ [Materials & Methods](#)
- ▼ [Results](#)
- ▼ [Discussion](#)
- ▼ [References](#)

region from North Africa to China as a remedy, especially in the traditional Ayurvedic medicine of India. In the eighties, it was reported that an ethanolic extract of *Boswellia* gum exerted anti-inflammatory and antiarthritic activities in animals (Singh and Atal, 1986; Reddy *et al.*, 1987). In an effort to find novel biologically active principles from plant origin, we observed that frankincense extracts inhibited leukotriene biosynthesis *in vitro* (Ammon *et al.*, 1991). As active principles, we identified boswellic acids that belong to ursane-type pentacyclic triterpene saponines, and we demonstrated that boswellic acids selectively blocked leukotriene biosynthesis (Safayhi *et al.*, 1992). The boswellic acid derivative AKBA inhibited 5-LO, the key enzyme of leukotriene biosynthesis, by an enzyme-directed, nonredox and noncompetitive mechanism *via* binding to a pentacyclic triterpene-selective effector site (Safayhi *et al.*, 1995; Sailer *et al.*, 1996a).

However, in 1991 we observed that boswellic acids also prevent endotoxin-/galactosamine-induced hepatitis in mice (Safayhi *et al.*, 1991). This observation was intriguing, because it had been reported that protection against endotoxic shock could be achieved only by less selective lipoxygenase blockers, not by site-specific leukotriene biosynthesis inhibitors (Schade *et al.*, 1991; Schade *et al.*, 1992), and that 5-LO-deficient transgenic mice showed no difference in their reaction to endotoxin shock (Chen *et al.*, 1994). In 1991, it was reported that the pentacyclic triterpene ursolic acid inhibited HLE (EC3.4.21.37) (Ying *et al.*, 1991). HLE is a serine protease produced and released by PMNL, and because of its aggressive destructiveness, some investigators have suggested that HLE may play a role in several diseases, such as pulmonary emphysema, cystic fibrosis, chronic bronchitis, acute respiratory distress syndrome, glomerulonephritis and rheumatic arthritis (for review see Bernstein *et al.*, 1994). In 1995, it was demonstrated that granulocyte-mediated hepatotoxicity after endotoxin stimulation depends on elastase release (Sauer *et al.*, 1995).

The aim of this study was to determine whether the established pentacyclic triterpene-type 5-LO inhibitor AKBA also affects the activity of HLE. Here, we report that many pentacyclic triterpenes, including the boswellic acids, block HLE activity *in vitro* but that the combined inhibition of two pathophysiologically important enzyme activities (those of HLE and 5-LO) in an independent manner is unique to pentacyclic triterpenes from the boswellic acid series.

## ► Materials and Methods


**Chemicals.** Ursolic acid, 18 $\beta$ -glycyrrhetic acid, amyirin (a mixture of isomeric  $\alpha$ - and  $\beta$ -forms) was purchased from Roth (Karlsruhe, FRG, both Rotichrom GC grade). AKBA and  $\beta$ -boswellic acid were purified and characterized by spectroscopy (infrared,  $^1\text{H}$ -NMR and mass) (see fig. 1 for structures), by thin-layer chromatography, by elemental analyses and by their melting points, as described in

detail elsewhere (Safayhi *et al.*, 1992; Sailer *et al.*, 1996b). NDGA, testosterone, cortisol, arachidonic acid (Na-salt), Suc-Ala-Ala-Pro-Phe-p-nitroanilide, MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide and

$\alpha_1$ -antitrypsin were obtained from Sigma (Deisenhofen, FRG). HLE was obtained from Calbiochem (Bad Soden, FRG), and chymotrypsin from Boehringer (Mannheim, FRG). MK-886 and ZM-230,487 (formerly ICI-230,487) were kind gifts from Dr. A.W. Ford-Hutchinson (Merck Frosst Centre for Therapeutic Research, Kirkland, Canada) and from Dr. G.C. Crawley (ICI & Zeneca Pharmaceuticals, Macclesfield,

- ▲ [Top](#)
- ▲ [Abstract](#)
- ▲ [Introduction](#)
- [Materials & Methods](#)
- ▼ [Results](#)
- ▼ [Discussion](#)
- ▼ [References](#)

Cheshire, England), respectively.



**Measurement of HLE activity.** The hydrolytic activity of HLE was measured using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate in PBS containing 10% DMSO (v/v) at 25°C (Bieth *et al.*, 1974<sup>□</sup>). Enzyme (20 nM) was preincubated for 5 min in the presence of test compounds or vehicle (DMSO). The final concentration of DMSO was 10.25% throughout. The reaction was started by the addition of substrate. The formation of p-nitroanilide (pNA) was monitored by detection at 405 nm for 5 min. Using a substrate concentration range from 10  $\mu$ M to 4 mM we calculated a  $K_m$  value of about 148 to 198  $\mu$ M and a  $V_{max}$  value of about 52 to 57 nanomoles per second for the commercial enzyme preparation, the variation depending on the linearization procedures used.

**Measurement of chymotrypsin activity.** The hydrolytic activity of chymotrypsin was measured using Suc-Ala-Ala-Pro-Phe-pNA as substrate in a Tris buffer containing 10 mM  $\text{CaCl}_2$  at 25°C (DelMar *et al.*, 1979<sup>□</sup>). Enzyme (40 nM) was preincubated for 5 min in the presence of test compounds or vehicle (DMSO). The reaction was started by the addition of substrate in DMSO. All incubations, including controls, were carried out in the presence of 10.25% DMSO. The formation of pNA was monitored by detection at 410 nm for 5 min.


**Data.** Product formation was calculated by comparison with a standard curve for pNA. Data on observations ( $n$  = number of experiments) are shown as means  $\pm$  S.D. Enzyme kinetic data were analyzed by constructing Lineweaver-Burk and Eadie-Hoffstee plots (Bisswanger, 1979<sup>□</sup>). The  $\text{IC}_{50}$  values were calculated by using GraphPad Prism software, version 2.0, for one-site competition (GraphPad Software, Inc., San Diego, CA). Statistical analysis was performed using Student's  $t$  test for unpaired data.

## Results

The pentacyclic triterpene AKBA, a direct, nonredox and noncompetitive 5-lipoxygenase inhibitor, blocked the hydrolysis of MeO-Suc-Ala-Ala-Pro-Val-pNA by HLE in a concentration-dependent manner, as shown in figure 2. The  $\text{IC}_{50}$  value for AKBA was  $13.8 \pm 2.0 \mu\text{M}$  ( $n = 5$ ). The pentacyclic triterpene ursolic acid, which possesses no 5-LO inhibitory properties,

- ▲ [Top](#)
- ▲ [Abstract](#)
- ▲ [Introduction](#)
- ▲ [Materials & Methods](#)
- [Results](#)
- ▼ [Discussion](#)
- ▼ [References](#)

blocked the activity of HLE with  $IC_{50}$  values of  $0.9 \pm 0.6 \mu\text{M}$  (at  $50 \mu\text{M}$  substrate,  $n = 3$ ) to  $2.4 \pm 0.2 \mu\text{M}$  (at  $500 \mu\text{M}$  substrate,  $n = 3$ ). Among the pentacyclic triterpenes, a substantial elastase inhibition was also observed by  $\beta$ -boswellic acid and amyrin, but not by  $18\beta$ -glycyrrhetic acid in concentrations up to  $20 \mu\text{M}$  (table 1). The HLE activity was also not decreased by various other noncyclic or cyclic lipophilic compounds (*e.g.*, arachidonic acid, cortisol and testosterone) in comparable concentrations.



View larger version (21K):  
[\[in this window\]](#)  
[\[in a new window\]](#)

**Fig. 2.** Inhibition of HLE activity by AKBA (panel A) and ursolic acid (panel B). Substrate (MeO-Suc-Ala-Ala-Pro-Val-pNA) concentrations were  $50 (\blacksquare)$ ,  $100 (\blacktriangle)$ ,  $150 (\blacktriangledown)$ ,  $300 (\blacklozenge)$  and  $500 \mu\text{M} (\odot)$ . The assays were carried out in PBS/10.25% DMSO, pH 7.2, at  $25^\circ\text{C}$ . The enzyme concentration was  $20 \text{ nM}$ . Data are shown as absolute values of pNA release, in nanomoles per minute, as means  $\pm$  S.D. of three experiments.


View this table:  
[\[in this window\]](#)  
[\[in a new window\]](#)

**TABLE 1**  
**HLE activity in the presence of various cyclic and noncyclic hydrophobic compounds and leukotriene biosynthesis inhibitors**

The assay was performed using MeO-Suc-Ala-Ala-Pro-Val-pNA as substrate in PBS, pH 7.2, containing 10.25% DMSO at  $25^\circ\text{C}$ . The HLE concentration was  $20 \text{ nM}$ , and the substrate concentration was  $100 \mu\text{M}$ . Test compounds were assayed at a final concentration of  $20 \mu\text{M}$  throughout. Data are shown as absolute values of pNA release in nanomoles per minute (mean  $\pm$  S.D.; \*\*\* $P < .001$  vs. DMSO controls) in three experiments or percent of HLE activity in controls.


Again in contrast to the inhibitory effect of the direct, nonredox and noncompetitive 5-LO inhibitor AKBA on HLE, other leukotriene biosynthesis inhibitors from different chemical classes exerted no HLE inhibitory activity. As shown in table 1, no substantial inhibition of HLE was observed by the redox-type 5-LO inhibitor NDGA, by the so-called translocation inhibitor MK-886 or by the nonredox-type-competitive 5-LO inhibitor ZM-230,487.

As illustrated in figures 3 and 4 by secondary Lineweaver-Burk and Eadie-Hofstee plots, data analyses indicate different mechanisms for the inhibitory actions of the pentacyclic triterpenes AKBA and ursolic acid. The mode of inhibition was noncompetitive with AKBA but competitive with ursolic acid.



View larger version (15K):  
[\[in this window\]](#)  
[\[in a new window\]](#)

**Fig. 3.** Lineweaver-Burk plots of the HLE inhibition by AKBA (panel A) and ursolic acid (panel B) with MeO-Suc-Ala-Ala-Pro-Val-pNA as substrate. Velocity ( $v$ ) is expressed in nanomoles pNA per minute, and the substrate concentration ( $A$ ) in micromoles per liter. Substrate concentrations were 50, 100, 150, 300 and 500  $\mu$ M in panel A and 50, 100, 300 and 500  $\mu$ M in panel B. Inhibitor concentrations were 0 (\*), 12.5 ( $\diamond$ ), 17.5 (+) and 20 ( $\times$ )  $\mu$ M AKBA in panel A, and 0 (\*), 1 ( $\diamond$ ), 2.5 (+) and 7.5 ( $\times$ )  $\mu$ M ursolic acid in panel B.



View larger version (19K):  
[\[in this window\]](#)  
[\[in a new window\]](#)

**Fig. 4.** Eadie-Hofstee plots of the HLE inhibition by AKBA (panel A) and ursolic acid (panel B) with MeO-Suc-Ala-Ala-Pro-Val-pNA as substrate. Velocity ( $v$ ) is expressed in nanomoles pNA per minute, and the substrate concentration ( $A$ ) in micromoles per liter. Substrate concentrations were 50, 100, 150, 300 and 500  $\mu$ M in (panel A) and 50, 100, 300 and 500  $\mu$ M in (panel B). Inhibitor concentrations were 0 (\*), 12.5 ( $\diamond$ ), 17.5 (+) and 20 ( $\times$ )  $\mu$ M AKBA in (A); 0 (\*), 1 ( $\diamond$ ), 2.5 (+) and 7.5 ( $\times$ )  $\mu$ M ursolic acid in (B).

In order to determine whether AKBA also impairs nonselectively the activities of other serine proteases, we evaluated its effect on chymotrypsin activity. As shown in table 2, no prominent inhibition by AKBA of chymotrypsin was observed in concentrations up to 100  $\mu$ M, whereas ursolic acid decreased the chymotrypsin activity by about 70% at a high concentration of 100  $\mu$ M.

View this table:  
[\[in this window\]](#)  
[\[in a new window\]](#)

**TABLE 2**  
**Chymotrypsin activity in the presence AKBA, ursolic acid and  $\alpha_1$ -antitrypsin with Suc-Ala-Ala-Pro-Phe-pNA as substrate**

The assay was performed in PBS containing 10.25% DMSO, pH 7.2, at 25°C. Final concentrations were 40 nM for chymotrypsin, 100  $\mu$ M for substrate and 3.8  $\mu$ M for  $\alpha_1$ -antitrypsin ( $n = 3$ ; \* $P < .05$ ; \*\* $P < .01$  and \*\*\* $P < .001$ ).

## Discussion

The boswellic acid derivatives AKBA and  $\beta$ -boswellic acid, as well as amyrin, inhibited the hydrolysis of a synthetic substrate by purified HLE *in vitro*, as was previously reported for other pentacyclic triterpenes (*i.e.*, ursolic acid, oleanolic acid, uvaol and erythrodiol (Ying *et al.*, 1991)). Although the *in vitro* test system that we used contains substantial amounts of organic solvent and, therefore, would have permitted the addition of test compounds in greater quantities for screening purposes, we limited the final concentrations to 20  $\mu$ M because higher plasma levels are not likely with the lipophilic pentacyclic

- ▲ [Top](#)
- ▲ [Abstract](#)
- ▲ [Introduction](#)
- ▲ [Materials & Methods](#)
- ▲ [Results](#)
- [Discussion](#)
- ▼ [References](#)

triterpenes. With 20  $\mu$ M in each case, we observed *in vitro* no substantial HLE inhibition by 18 $\alpha$ -glycyrrhetic acid, cortisol, testosterone or arachidonic acid.

We previously reported that many pentacyclic triterpenes also bind to 5-LO, the key enzyme of leukotriene biosynthesis (Safayhi *et al.*, 1995 $\square$ ). The presence of an 11-keto-group and a hydrophilic function on ring A of the pentacyclic ring system are crucial for potent inhibition of 5-LO, and ursolic acid and amyrin turned out to be noninhibitory (Sailer *et al.*, 1996a $\square$ ). Thus the structure requirements for the 5-LO inhibitory activity of pentacyclic triterpenes are more rigid than those for HLE inhibitory activity. Our data are in line with the hypothesis that pentacyclic triterpenes interact with the extended substrate binding domain in the HLE that can accommodate a variety of hydrophobic ligands (Ashe and Zimmerman, 1977 $\square$ ; Cook and Ternai, 1988 $\square$ ; Ying *et al.*, 1991 $\square$ ). With a pentapeptide substrate, we observed competitive-type HLE inhibition by ursolic acid, but a noncompetitive mode of inhibition by AKBA (figs. 3 and 4). The reason for this difference is not obvious, but it is a general property of HLE inhibition. For example, oleic acid derivatives have been described as both competitive and noncompetitive inhibitors of HLE (Tyagi and Simon, 1990 $\square$ ; Ashe and Zimmerman, 1977 $\square$ ; Hornebeck *et al.*, 1995), and, depending on substrate length, different mechanisms have also been reported for ursolic acid (Ying *et al.*, 1991 $\square$ ).

In summary, boswellic acids with 5-LO inhibitory activity block HLE activity. HLE inhibition is established for many lipophilic compounds, but a dual HLE and 5-LO inhibitory property is unique to pentacyclic triterpenes from the boswellic acid series. Because leukotriene levels and HLE release are increased in parallel in many inflammatory diseases and hypersensitivity-based reactions (Mayatepek and Hoffmann, 1995 $\square$ ; Bernstein *et al.*, 1994 $\square$ ), boswellic acid derivatives such as AKBA might provide a tool to help us cope better with such pathophysiological processes. In line with this hypothesis, boswellic acid containing crude extracts of the *Boswellia* resin have been recently reported to inhibit the increased urinary excretion of leukotriene E<sub>4</sub> in astrocytoma patients *in vivo* and to block leukotriene biosynthesis *ex vivo* (Heldt *et al.*, 1996 $\square$ ).

## ► Footnotes

Accepted for publication December 24, 1996.

Received for publication June 18, 1996.

**Send reprint requests to:** Privat-Dozent Dr. H. Safayhi, Institute of Pharmaceutical Sciences, University of Tuebingen, Auf der Morgenstelle 8, D-72076 Tuebingen, Germany.

## ► Abbreviations

AKBA, acetyl-11-keto- $\beta$ -boswellic acid; DMSO, dimethylsulfoxide; HLE, human leukocyte elastase; 5-LO, 5-lipoxygenase; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; MK-886 (formerly designated L-663, 536),

3-[1-(4-chlorobenzyl)-3-tert-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid; NDGA, nordihydroguaiaretic acid; PBS, Dulbecco's phosphate-buffered saline; PMNL, polymorphonuclear leukocytes; ZM-230, 487 (formerly designated ICI-230,487: the N-ethyl-analog of ICI-D2138),

6-[[3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy]methyl]-1-ethylquinol-2-one.

703 836 - 2021

## References

[▲ Top](#)  
[▲ Abstract](#)  
[▲ Introduction](#)  
[▲ Materials & Methods](#)  
[▲ Results](#)  
[▲ Discussion](#)  
[▲ References](#)

- Ammon, H. P. T., Mack, T., Singh, G. B. and Safayhi, H.: Inhibition of leukotriene B<sub>4</sub> formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of *Boswellia serrata*. *Planta Med.* **57**: 203-207, 1991[[Medline](#)].
- Ashe, B. M. and Zimmerman, M.: Specific inhibition of human granulocyte elastase by *cis*-unsaturated fatty acids and activation by the corresponding alcohols. *Biochem. Biophys. Res. Commun.* **75**: 194-199, 1977[[Medline](#)].
- Bernstein, P. R., Edwards, P. D. and Williams, J. C.: Inhibitors of human leukocyte elastase. *In* Progress in Medicinal Chemistry 37 ed. by G. P. Ellis, and D. K. Luscombe, pp. 59-120, Elsevier, Amsterdam, 1994.
- Bieth, J., Spiess, B. and Wermuth, C. G.: The synthesis and analytical use of a highly sensitive and convenient substrate of elastase. *Biochem. Med.* **11**: 350-357, 1974[[Medline](#)].
- Bisswanger, H.: Theorie und Methoden der Enzymkinetik., Verlag Chemie, Weinheim, 1979.
- Chen, X. S., Sheller, J. R., Johnson, E. N. and Funk, C. D.: Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. *Nature (Lond.)* **372**: 179-182, 1994[[Medline](#)].
- Cook, L. and Ternai, B.: Similar binding sites for unsaturated fatty acids and alkyl 2-pyrone inhibitors of human sputum elastase. *Biol. Chem. Hoppe-Seyler* **369**: 627-631, 1988[[Medline](#)].
- DelMar, E. G., Largman, C., Brodrick, J. W. and Geokas, M. C.: A sensitive new substrate for chymotrypsin. *Anal. Biochem.* **99**: 316-320, 1979[[Medline](#)].
- Heldt, R. M., Winking, M. and Simmet, T.: Cysteinyl-leukotrienes as potential mediators of the peritumoral brain oedema in astrocytoma patients (Abstract). *Naunyn-Schmiedeberg's Arch. Pharmacol.* **353 4S**: R142 538, 1996.
- Hornebeck, W., Moczar, E., Szecsi, J. and Robert, L.: Fatty acid peptide derivatives as model compounds to protect elastin against degradation by elastases. *Biochem. Pharmacol.* **34**: 3315-3321, 1985[[Medline](#)].
- Martinetz, D., Lohs, K. and Janzen, J.: Weihrauch und Myrrhe: Kulturgeschichtliche und wirtschaftl. In Bedeutung; Botanik, Chemie, Medizin. Wiss., Verl.-Ges., Stuttgart, 1988.
- Mayatepek, E. and Hoffmann, G. F.: Leukotrienes: Biosynthesis, metabolism, and pathophysiologic significance. *Pediatr. Res.* **37**: 1-9, 1995[[Medline](#)].
- Reddy, G. K., Dhar, S. C. and Singh, G. B.: Urinary excretion of connective tissue metabolites under the influence of a new non-steroidal anti-inflammatory agent in adjuvant induced arthritis. *Agents Actions* **22**: 99-105, 1987[[Medline](#)].
- Safayhi, H., Mack, T. and Ammon, H. P. T.: Protection by boswellic acids against galactosamine/endotoxin-induced hepatitis in mice. *Biochem. Pharmacol.* **41**: 1536-1537, 1991[[Medline](#)].
- Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M. I., Subramanian, L. R. and Ammon, H. P. T.: Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. *J. Pharmacol. Exp. Ther.* **261**: 1143-1146, 1992[[Abstract](#)].
- Safayhi, H., Sailer, E.-R. and Ammon, H. P. T.: Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto- $\beta$ -boswellic acid. *Mol. Pharmacol.* **47**: 1212-1216, 1995[[Abstract](#)].
- Sailer, E.-R., Hoernlein, R. F., Subramanian, L. R., Ammon, H. P. T. and Safayhi, H.: Preparation of novel analogues of the nonredox-type, non-competitive leukotriene biosynthesis inhibitor AKBA. *Archiv. Pharm.* **329**: 54-56, 1996b.
- Sailer, E.-R., Subramanian, L. R., Rall, B., Hoernlein, R. F., Ammon, H. P. T. and Safayhi, H.: Acetyl-11-keto- $\beta$ -boswellic acid (AKBA): Structure requirements for binding and 5-lipoxygenase inhibitory activity. *Br. J. Pharmacol.* **117**: 615-618, 1996a[[Abstract](#)].

- Sauer, A., Aigner, J., Hartung, T., Minuth, W. and Wendel, A.: Granulocyte mediated hepatotoxicity after endotoxin stimulation depends on adhesion and elastase release. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **351S**: A495, 1995.
- Schade, U. F., Engel, R. and Jakobs, D.: Differential protective activities of site specific lipoxigenase inhibitors in endotoxic shock and production of tumor necrosis factor. *Int. J. Immunopharmacol.* **13**: 565-571, 1991[[Medline](#)].
- Schade, U. F., Engel, R. and Jakobs, D.: Lipoxigenase inhibitors but not site specific 5-lipoxygenase blockers protect against endotoxic shock and inhibit production of tumor necrosis factor. *Eicosanoids* **5S**: S45-S47, 1992.
- Singh, G. B. and Atal, C. K.: Pharmacology of an extract of salai guggal ex-*Boswellia serrata*, a new non-steroidal anti-inflammatory agent. *Agents Actions* **18**: 407-412, 1986[[Medline](#)].
- Tyagi, S. C. and Simon, S. R.: Inhibitors directed to binding domains in neutrophil elastase. *Biochemistry* **29**: 9970-9977, 1990[[Medline](#)].
- Ying, Q.-L., Rinehart, A. R., Simon, S. R. and Cheronis, J. C.: Inhibition of human leucocyte elastase by ursolic acid. *Biochem. J.* **277**: 521-526, 1991[[Medline](#)].

0022-3565/97/2811-0460\$03.00/0

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics

## This article has been cited by other articles:

- Hoernlein, R. F., Orlikowsky, Th., Zehrer, C., Niethammer, D., Sailer, E. R., Simmet, Th., Dannecker, G. E., Ammon, H. P. T. (1999). Acetyl-11-Keto-beta -Boswellic Acid Induces Apoptosis in HL-60 and CCRF-CEM Cells and Inhibits Topoisomerase I. *J. Pharmacol. Exp. Ther.* **288**: 613-619 [[Abstract](#)] [[Full Text](#)]

- ▶ [Abstract of this Article](#)
- ▶ [Reprint \(PDF\) Version of this Article](#)
- ▶ [eLetters: Submit a response to this article](#)
- ▶ Similar articles found in:
  - [JPET Online](#)
  - [PubMed](#)
- ▶ [PubMed Citation](#)
- ▶ This Article has been cited by:
- ▶ Search Medline for articles by:  
[Safayhi, H.](#) || [Ammon, H. P. T.](#)
- ▶ Alert me when:  
[new articles cite this article](#)
- ▶ [Download to Citation Manager](#)

[HOME](#) [HELP](#) [FEEDBACK](#) [SUBSCRIPTIONS](#) [ARCHIVE](#) [SEARCH](#) [TABLE OF CONTENTS](#)[ALL ASPET JOURNALS](#) [MOLECULAR PHARMACOLOGY](#) [PHARMACOLOGICAL REVIEWS](#)  
[J PHARMACOL EXP THER](#) [THERAPEUTICS](#) [MOLECULAR INTERVENTIONS](#) [DRUG METABOLISM & DISPOSITION](#)




also block this enzyme, but they do so in a more general fashion, as an antioxidant; whereas Boswellia seems to be a specific inhibitor of 5-LOx. It is known that non-steroidal anti-inflammatory drugs can cause a disruption of glycosaminoglycan synthesis which can accelerate the articular damage in arthritic conditions. A recent in-vivo study examined BS and ketoprofen for their effects on glycosaminoglycan metabolism. BS significantly reduced the degeneration of GAGs compared to controls, whereas ketoprofen caused a reduction in total tissue GAG content. In addition Boswellic Acids inhibited antibody production as well as infiltration of polymorphonuclear leucocytes thereby reducing inflammatory effect. In conclusion there is considerable research to support the highly beneficial properties of standardized Boswellic Acids in inflammatory conditions.

Anti-complement Activity BSE also demonstrated a marked inhibitory effect on both the classical and alternate complement systems. Analgesic Activity An investigation of BSE's analgesic and psychopharmacologic effects noted that it "was found to exhibit marked sedative and analgeric effects" in animals. Inflammatory Bowel Syndrome (IBS) Leukotrienes are suggested to play a role in the inflammatory process of ulcerative colitis (UC). BSE 350mg three times a day was comparable to sulfasalazine (at 1g three times a day) a standard prescriptive drug in UC. Other biological activities BSE have also been observed to inhibit human leukocyte elastase (HLE), which may be involved in the pathogenesis of emphysema. HLE also stimulates mucus secretion and thus may play a role in cystic fibrosis, chronic bronchitis, and acute respiratory distress syndrome.


#### Reference

- i. Safaychi, H. et-al (1992) "Boswellic acids: novel, specific, non redox inhibitors of 5-lipoxygenase". *J. Pharmacol. Exp. Ther.*; 261: 1143.
- ii. Ammon, H.P et-al (1991) "Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum-resin exudate of *Boswellia Serrata*" *Planta-Med.*; 57: 203.
- iii. Reddy, G.K et-al (1988) "Effect of Salaki guggal ex-*Boswellia Serrata* on cellular and humoral immune responses and leucocyte migration." *Agents and Action*; 24: 161.
- iv. Kulkarni, R. R et-al (1991) "Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled study". *J. Ethnopharmacol.*; 33:91.
- v. 11th European Congress of Rheumatology Vol 5/8-2 Suppl. Issue 1987.
- vi. Atal, C.K. et-al (1984) "Salaki guggal a new NSAID and its probable mode of action" *Recent advances in Mediators Inflammation and Anti inflammatory Agents. Symp.* Nov 2-4.
- vii. Menon, M.K. and Khar, A. (1971) "Analgesic and Psychopharmacological effects of gum resin of *Boswellia Serrata*" *Planta Medica*; 19:332-336.
- viii. Reddy, G.K. et-al (1981) "Studies on the metabolism of glycoaminoglycans under the influence of new herbal anti-inflammatory agents". *Biochemical Pharmacol.*, 38

 = Check & for act.

HLE link possibly  
in one of these  
refs.

35271989ix. Singh, G.B. and Atal, C.K.(1990)  
"Pharmacology of an extract of *Boswellia Serrata*, a new  
non-steroidal anti-inflammatory agents". *Agents Action*;  
18: 407-412.



## Ayurvedic Products

Acti-cyclase

Adaptogen

Bosiritis caps/cream

Chirantins

Curcumin

DB-TENE

Feminix

Ashwagandha

Gymnema

Initialy

LIV 104

Maxi-BOZ

Memorex

Nimbidin

Opti-Guggul

Osti Mend

Phyllanthus

Shilajit

Tribal Powder

Triphlax

Gastromet

Renomet

**90 Capsules HI1816 100% Vegetarian Each 500mg capsule contains Boswellia Serrata 500mg (Standardized to 65% Boswellic Acid)**

**Suggested Use** Take one to three capsules daily or as directed by a qualified health care practitioner.

**Main Applications** As reported by literature: -Asthma. -Anti-inflammatory. -skin disorders. -Inflammatory Bowel Disease.

**Origin** generally found in dry hilly areas of India.


**Source** Boswellia serrata, is a moderate to large branching tree generally found in dry hilly area of India. The tree exudes a gummy oleo-resin when it is tapped by scrapping away a portion of the bark. The chemical constituents of the gum resin include volatile oils, erpinols, terpens, sugars and gum.

**Pregnancy / Nursing** Has not been studied.

**Interactions** None.

There are many medicinal plants of great therapeutic value referred to in the ancient treatment systems of Ayurveda. One particular plant of much repute is resin of the tree Boswellia serrata (BSE), or Frankenscience which the ayurvedic materia medica claimed to have potent anti-inflammatory and anti-arthritis properties.

Pharmacological properties include: Anti-inflammatory Activity Ethanol extracts of the resin demonstrated reduced carrageenan induced paw edema in normal rats and mice as well as in adrenalectomized rats. Further extracts showed anti-arthritis activity in formaldehyde and adjuvant- induced arthritis in rats and BSA induced arthritis in the rabbit. In addition the researchers found the above extract to be more beneficial, less toxic and more potent than the standard drug of choice Ketoprofen, a widely used perscriptive Non-steroidal Anti-inflammatory drug (NSAID). More recently a number of researchers have identified the anti-inflammatory activity of the ethanoilc extracts of the resin to be due to Boswellic Acids in particular the alpha and beta isomers. Recently, a more purified compound standardized for 65% Boswellic Acids has shown potent anti-inflammatory and anti-arthritis activity without any of the adverse effects eg. gastro-intestinal, CNS and cardiovascular. The mechanism of action of Boswellic Acids is similar to the action of NSAID's. Prostaglandins and leukotriens are two classes of arachidonic acid derived mediators of inflammation. Leukotriens, for which 5-lipoxygenase (5-LOX) is the key enzyme in synthesis are considered to be involved in the initiation and maintenance of various inflammatory disease for example arthritis, Chron's disease, ulcerative colitis, asthma etc. Boswellic Acids are potent inhibitor of 5-lipoxygenase product, including 5-hydroxyeiconatetraenoic acid (5HETE), and leukotriene B4 (LTB4), which caused bronchoconstriction, chemotaxis, and increases vascular permeability. Other anti-inflammatory plant constituents, such as quercetin,



## Contact Us

In Canada

Ph: 1 800 387 0177

Fax: 1 877 219 9974

International

Ph: 403 250 7849

Fax: 403 250 9974

**BOSWELLIN®****Introduction****Mechanism of  
Anti-inflammatory Action****Pharmacological Effects of  
Boswellic Acids** \***Summary of Patents on  
Boswellic Acids** \***Glossary****Boswellin-Booklet****Contact Us****HOME****References**

1. Majeed, M. Prakash, L., Badmaev, V., Nujoma, Y., Natarajan, S., Norton, T., Sysler, M., Gopinathan, S., and Alegesan, K (1999) *Redefining Our Standards, Boswellin® The Only Natural Leukotriene and HLE Inhibitor*. Sabinsa Corporation.
2. Majeed, M., Badmaev, V., Gopinathan, S., Rajendran, R., Norton, T., and Braly, J. (1996) *Boswellin® The Anti-inflammatory Phytonutrient*. Nutriscience Publishers Inc., Piscataway, NJ.
3. Henderson, W.R. (1994) The role of leukotrienes in inflammation. *Ann. Intern. Med.* 121, 684-697.
4. Ford Hutchinson, A.W. Gresser, M., and Young, R.N. (1993) 5-Lipoxygenase. *Ann. Rev. Biochem.* 63, 383-417.
5. Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M.I., Subramanian, L.R., and Ammon, H.P.T. (1992) Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. *J. Pharmacol. Exp. Ther.* 261(3), 1143-1146.
6. Sailer, E-R., Subramanian, L.R., Rall, B., Hoernlein, R.F., Ammon, H.P.T., and Safayhi, H. (1996) Acetyl-11-keto-b-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. *Br. J. Pharmacol.* 117, 615-618.
7. Sailer, E-R.; Schweizer, S., Boden, S.E., Ammon, H.P.T., and Safayhi, H. (1998) Characterization of acetyl-11-keto-b-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. *Eur. J. Biochem.* 256, 364-368.
8. Aharony, D. and Stein, R.L. (1986) Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. *J. Biol. Chem.* 261, 11512-11519.
9. Werz, O., Szellas, D., Henseler, M., and Steinhilber, D. (1998) Nonredox 5-Lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. *Molecular Pharmacology* 54, 445-451.
10. Lau, C.K., Belanger, P.C., Dufresne C., Scheiget, J., Therien, M., Fitzsimmons, B., Young, R.N., Ford-Hutchinson, A.W., Riendeau, D., Denis, D., Guay, J., Charleson, S., Piechuta, H., McFarlane, C.S., Chiu, S.H.L., Eline, D., Alvaro, R.F., Miwa, G., and Walsh, J.L. (1992) Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase. *J. Med. Chem.* 35, 1299-1318.
11. Safayhi, H., Rall, B., Sailer, E-R., and Ammon, H.P.T. (1997) Inhibition by boswellic acids of human leukocyte elastase. *J. Pharmacol. Exp. Ther.* 281, 460-463.
12. Ellis, R.E., Yuan, J.Y., and Horvitz, H.R. (1991) Mechanisms and functions of cell death. *Ann. Rev. Cell. Biol.* 7, 663-698.

- \* 13. Raff, M.C., Barres, B.A., Burne, J.F., Coles, H.S., Ishizaki, Y., and Jacobson, M.D. (1993) Programmed cell death and the control of cell survival: Lessons from the nervous system. *Science (Washington DC)* **262**, 695-700.
14. Rougier, P. and Bugat, R. (1996) CPT-11 in the treatment of colorectal cancer: Clinical efficacy and safety profile. *Semin. Oncol.* **23**, 34-41.
- \* 15. Anderson, K.M., Seed, T., Plate, J.M., Jajeh, A., Meng, J., and Harris, J.E. (1995) Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. *Leukotr. Res.* **19**, 789-801.
16. Hoernlein, R.F., Orlikowsky, T.H., Zehrer, C., Niethammer, D., Sailer, E.R., Simmet, T.H., Dannecker, G.E., and Ammon, H.P.T. (1999) Acetyl-11-keto-b-Boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. *J. Pharm. Exp. Therap.* **288**(2), 613-619.
- \* 17. Lee, Y-W., Fang, Q-C., Wang, Z-G., Li, D-H., and Cook, C.E. (1991) Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers *US Patent 5,064,823*.
18. Wildfeuer, A., Neu, I.S., Safayhi, H., Metzger, G., Wehrmann, M., Vogel, U., and Ammon, H.P.T. (1998) Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis. *Arzneim.-Forsch. Drug Res.* **48**(1), Nr 6, 668-674.
19. Shao, Y., Ho, C-T., Chin, C-K., Badmaev, V., Ma, W., and Huang, M-T. (1998) Inhibitory activity of boswellic acids from *Boswellia serrata* against human leukemia HL-60 cells in culture. *Planta Medica* **64**, 328-331.
20. Jing, Y., Nakajo, S., Xia, L., Nakaya, K., Fang, Q., Waxman, S., and Han, R. (1999) Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. *Leukemia Research* **23**, 43-50.
21. Gupta, V.N., Yadav, D.S., Jain, M.P., and Atal, C.K. (1987) Chemistry and Pharmacology of the gum resin of *B. serrata*. *Indian Drugs* **24**(5), 221-231.
22. *Annual Report, Regional Research Laboratory (CSIR), Jammu, India (1987-88)*, pp 1-2.
- \* 23. Singh, G.B. et al. (1992) New phytotherapeutic agent for treatment of arthritis and allied disorders with novel mode of action. *IV and Int. Congress on Phytotherapy, Munich, Germany, Abstract SL 74*.
24. Böker, D-K. and Winking, M. (1997) *Dtsch. Ärzteblatt* **94**, 1197 (cited in reference 18).
25. Gupta, I., Parihar, A., Malhotra, P., Singh, G.B., Lüdtkke, R., Safayhi, H., and Ammon, H.P. (1997) Effects of *Boswellia serrata* gum resin in patients with ulcerative colitis. *Eur. J. Med. Res.*

2(1), 37-43.

26. Gupta, I., Gupta, V., Parihar, A., Gupta, S., Luedtke, R., Safayhi, H., and Ammon, H.P. (1998) Effects of *Boswellia serrata* gum resin in patients with bronchial asthma: results of a double blind, placebo-controlled, 6-week clinical study. *Eur. J. Med. Res.* 3(11), 511-514.
27. Simmet, T. and Ammon, H.P.T. (1998) Use of boswellic acid for treating brain tumours. *Patent WO 96/19212*.
28. Ammon, H.P.T. and Safayhi, H. (1997) Use of Boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity. *Patent WO 97/07796*.
29. Ammon, H.P.T., Safayhi, H.; and Singh, G.B. (1993) Use of pure boswellic acid. *Patent EP 0552657*.
30. Weisman, B. (1999) Natural composition for treating bone or joint inflammation. *US Patent 5,888,514*.
31. Taneja, S.C.; Sethi, V.K.; Dhar, K.L.; and Kapil, R.S. (1997) Boswellic acid compositions and preparation thereof. *US Patent 5,629,351*.
32. Patwardhan, B. (1996) Method of treating musculoskeletal disease and a novel composition therefor. *US Patent 5,494,668*.
33. Etzel, R. (1998) Use of incense in the treatment of alzheimer's disease. *US Patent 5,720,975*.

© Sabinsa Corporation 2001

## PHARMACOLOGY

And Experimental Therapeutics

Experimental Biology 2002

April 20-24 • New Orleans

Late-breaking deadline: February 25, 2002

HOME

HELP

FEEDBACK

SUBSCRIPTIONS

ARCHIVE

SEARCH

TABLE OF CONTENTS

Institution: US Patent & Trademark Office || [Sign In as Member/Non-Member](#) ||[Contact Subscription Administrator at your institution](#) || [FAQ](#)

Vol. 281, Issue 1, 460-463, 1997

## Inhibition by Boswellic Acids of Human Leukocyte Elastase

Hasan Safayhi, Beatrice Rall, Eckart-Roderich Sailer and Hermann P T. Ammon

Department of Pharmacology, Institute of Pharmaceutical Sciences, University of Tuebingen, Tuebingen, Germany

- ▶ [Abstract of this Article](#)
- ▶ [Reprint \(PDF\) Version of this Article](#)
- ▶ [eLetters: Submit a response to this article](#)
- ▶ Similar articles found in:
  - [JPET Online](#)
  - [PubMed](#)
- ▶ [PubMed Citation](#)
- ▶ This Article has been cited by:
  - [other online articles](#)
- ▶ Search Medline for articles by:
  - [Safayhi, H.](#) || [Ammon, H. P T.](#)
- ▶ Alert me when:
  - [new articles cite this article](#)
- ▶ [Download to Citation Manager](#)

### Abstract

Frankincense extracts and boswellic acids, biologically active pentacyclic triterpenes of frankincense, block leukotriene biosynthesis and exert potent anti-inflammatory effects. Screening for additional effects of boswellic acids on further proinflammatory pathways, we observed that acetyl-11-keto- $\beta$ -boswellic acid, an established direct, nonredox and noncompetitive 5-lipoxygenase inhibitor, decreased the activity of human leukocyte elastase (HLE) *in vitro* with an  $IC_{50}$  value of about 15  $\mu$ M.

Among the pentacyclic triterpenes tested in concentrations up to 20  $\mu$ M, we also observed substantial inhibition by  $\beta$ -boswellic acid, amyryl and ursolic acid, but not by 18 $\beta$ -glycyrrhetic acid. The data show that the dual inhibition of 5-lipoxygenase and HLE is unique to boswellic acids: other pentacyclic triterpenes with HLE inhibitory activities (e.g., ursolic acid and amyryl) do not inhibit 5-lipoxygenase, and leukotriene biosynthesis inhibitors from different chemical classes (e.g., NDGA, MK-886 and ZM-230,487) do not impair HLE activity. Because leukotriene formation and HLE release are increased simultaneously by neutrophil stimulation in a variety of inflammation- and hypersensitivity-based human diseases, the reported blockade of two proinflammatory enzymes by boswellic acids might be the rationale for the putative antiphlogistic activity of acetyl-11-keto- $\beta$ -boswellic acid and derivatives.

- ▲ [Top](#)
- [Abstract](#)
- ▼ [Introduction](#)
- ▼ [Materials & Methods](#)
- ▼ [Results](#)
- ▼ [Discussion](#)
- ▼ [References](#)

### Introduction

Frankincense is a gum resin secreted by trees of the genus *Boswellia* of Burseraceae. From the very beginning of human civilization, it has been used for therapeutic purposes (Martinetz *et al.*, 1988). In Europe, it was a component of the pharmacopoeia until the beginning of this century, and then, with the onset of the era of synthetic drugs, it fell into oblivion. Frankincense is still used in the

- ▲ [Top](#)
- ▲ [Abstract](#)
- [Introduction](#)
- ▼ [Materials & Methods](#)
- ▼ [Results](#)
- ▼ [Discussion](#)
- ▼ [References](#)

703 836 - 2021

## References

[▲ Top](#)  
[▲ Abstract](#)  
[▲ Introduction](#)  
[▲ Materials & Methods](#)  
[▲ Results](#)  
[▲ Discussion](#)  
[▲ References](#)

1. Ammon, H. P. T., Mack, T., Singh, G. B. and Safayhi, H.: Inhibition of leukotriene B<sub>4</sub> formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of *Boswellia serrata*. *Planta Med.* **57**: 203-207, 1991[[Medline](#)].
2. Ashe, B. M. and Zimmerman, M.: Specific inhibition of human granulocyte elastase by *cis*-unsaturated fatty acids and activation by the corresponding alcohols. *Biochem. Biophys. Res. Commun.* **75**: 194-199, 1977[[Medline](#)].
3. Bernstein, P. R., Edwards, P. D. and Williams, J. C.: Inhibitors of human leukocyte elastase. In *Progress in Medicinal Chemistry* 37 ed. by G. P. Ellis, and D. K. Luscombe, pp. 59-120, Elsevier, Amsterdam, 1994.
4. Bieth, J., Spiess, B. and Wermuth, C. G.: The synthesis and analytical use of a highly sensitive and convenient substrate of elastase. *Biochem. Med.* **11**: 350-357, 1974[[Medline](#)].
5. Bisswanger, H.: *Theorie und Methoden der Enzymkinetik.*, Verlag Chemie, Weinheim, 1979.
6. Chen, X. S., Sheller, J. R., Johnson, E. N. and Funk, C. D.: Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. *Nature (Lond.)* **372**: 179-182, 1994[[Medline](#)].
7. Cook, L. and Ternai, B.: Similar binding sites for unsaturated fatty acids and alkyl 2-pyrone inhibitors of human sputum elastase. *Biol. Chem. Hoppe-Seyler* **369**: 627-631, 1988[[Medline](#)].
8. DelMar, E. G., Largman, C., Brodrick, J. W. and Geokas, M. C.: A sensitive new substrate for chymotrypsin. *Anal. Biochem.* **99**: 316-320, 1979[[Medline](#)].
9. Heldt, R. M., Winking, M. and Simmet, T.: Cysteinyl-leukotrienes as potential mediators of the peritumoral brain oedema in astrocytoma patients (Abstract). *Naunyn-Schmiedeberg's Arch. Pharmacol.* **353 4S**: R142 538, 1996.
10. Hornebeck, W., Moczar, E., Szecsi, J. and Robert, L.: Fatty acid peptide derivatives as model compounds to protect elastin against degradation by elastases. *Biochem. Pharmacol.* **34**: 3315-3321, 1985[[Medline](#)].
11. Martinetz, D., Lohs, K. and Janzen, J.: Weihrauch und Myrrhe: Kulturgeschichtliche und wirtschaftl. In *Bedeutung; Botanik, Chemie, Medizin. Wiss., Verl.-Ges., Stuttgart*, 1988.
12. Mayatepek, B. and Hoffmann, G. F.: Leukotrienes: Biosynthesis, metabolism, and pathophysiologic significance. *Pediatr. Res.* **37**: 1-9, 1995[[Medline](#)].
13. Reddy, G. K., Dhar, S. C. and Singh, G. B.: Urinary excretion of connective tissue metabolites under the influence of a new non-steroidal anti-inflammatory agent in adjuvant induced arthritis. *Agents Actions* **22**: 99-105, 1987[[Medline](#)].
14. Safayhi, H., Mack, T. and Ammon, H. P. T.: Protection by boswellic acids against galactosamine/endotoxin-induced hepatitis in mice. *Biochem. Pharmacol.* **41**: 1536-1537, 1991[[Medline](#)].
15. Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M. I., Subramanian, L. R. and Ammon, H. P. T.: Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. *J. Pharmacol. Exp. Ther.* **261**: 1143-1146, 1992[[Abstract](#)].
16. Safayhi, H., Sailer, E.-R. and Ammon, H. P. T.: Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto- $\beta$ -boswellic acid. *Mol. Pharmacol.* **47**: 1212-1216, 1995[[Abstract](#)].
17. Sailer, E.-R., Hoernlein, R. F., Subramanian, L. R., Ammon, H. P. T. and Safayhi, H.: Preparation of novel analogues of the nonredox-type, non-competitive leukotriene biosynthesis inhibitor AKBA. *Archiv. Pharm.* **329**: 54-56, 1996b.
18. Sailer, E.-R., Subramanian, L. R., Rall, B., Hoernlein, R. F., Ammon, H. P. T. and Safayhi, H.: Acetyl-11-keto- $\beta$ -boswellic acid (AKBA): Structure requirements for binding and 5-lipoxygenase inhibitory activity. *Br. J. Pharmacol.* **117**: 615-618, 1996a[[Abstract](#)].